{"schema_version":"1","generated_at":"2026-10-28T07:56:47.799Z","data_as_of":null,"url":"https://www.findmykol.com/kol/bouthaina-dabaja","json_url":"https://www.findmykol.com/kol/bouthaina-dabaja/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"bouthaina-dabaja","name":"Bouthaina Dabaja","credential":"MD","specialty":"Radiation Oncology","specialty_raw":"Radiation Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"The University of Texas MD Anderson Cancer Center","institution_url":"https://www.findmykol.com/institution/the-university-of-texas-md-anderson-cancer-center","city":"Houston","state":"TX","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"npi":"1225137896","orcid":"0000-0002-1226-0681","openalex":"A5007688820"},"summary":"Bouthaina Dabaja is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 398 publications with 8,891 citations (h-index 48); ClinicalTrials.gov lists 7 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":398,"cited_by_count":8891,"h_index":48,"latest_activity_year":2025,"source":"works"},"trials":{"count":7,"shown":3,"withheld":8,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT05357794","title":"Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"M.D. Anderson Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT05357794","trial_url":"https://www.findmykol.com/trial/NCT05357794"},{"nct":"NCT05035706","title":"Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors","phase":"EARLY_PHASE1","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"M.D. Anderson Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT05035706","trial_url":"https://www.findmykol.com/trial/NCT05035706"},{"nct":"NCT05011045","title":"Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies","status":"RECRUITING","role":"Overall official","sponsor":"M.D. Anderson Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT05011045","trial_url":"https://www.findmykol.com/trial/NCT05011045"}],"source":"trials"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":1,"shown":1,"withheld":0,"rows":[{"payer":"Kite Pharma, Inc.","program_year":2023,"amount_usd":25.63,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1225137896"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1225137896","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","year":2025,"journal":"Nature","source_url":"https://doi.org/10.1038/s41586-025-09655-y","status":"verified"},{"title":"Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia","year":2023,"journal":"Journal of Hematology & Oncology","source_url":"https://doi.org/10.1186/s13045-023-01444-2","status":"verified"},{"title":"NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022","year":2022,"journal":"Journal of the National Comprehensive Cancer Network","source_url":"https://doi.org/10.6004/jnccn.2022.0021","status":"verified"},{"title":"Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group","year":2021,"journal":"International Journal of Radiation Oncology*Biology*Physics","source_url":"https://doi.org/10.1016/j.ijrobp.2021.02.011","status":"verified"},{"title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma","year":2020,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2020001837","status":"verified"}],"source":"works"},"contact":{"address_1":"1515 HOLCOMBE BLVD","city":"Houston","state":"TX","zip":"770304000","phone":"713-792-6161","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1225137896","source":"identity"},"similar":[{"name":"Hagop Kantarjian","slug":"hagop-kantarjian","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/hagop-kantarjian","json_url":"https://www.findmykol.com/kol/hagop-kantarjian/profile.json"},{"name":"Gabriel Hortobagyi","slug":"gabriel-hortobagyi","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/gabriel-hortobagyi","json_url":"https://www.findmykol.com/kol/gabriel-hortobagyi/profile.json"},{"name":"Jaffer Ajani","slug":"jaffer-ajani","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/jaffer-ajani","json_url":"https://www.findmykol.com/kol/jaffer-ajani/profile.json"},{"name":"Funda Meric-Bernstam","slug":"funda-meric-bernstam","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Surgery","url":"https://www.findmykol.com/kol/funda-meric-bernstam","json_url":"https://www.findmykol.com/kol/funda-meric-bernstam/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":8,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2022-02-03","provider_certified":"2022-02-03","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}